InCellChem，Cell Culture, Antibody,IHC,IF

InCellChem

We Devoted Ourselves To The Development Of Biomedical Research Reagent.

PRODUCT

[Apoptosis]

Brassinolide,72962-43-7,IC-0200147

Price : $75.00Price : ￥750.00

Brassinolide is a plant growth regulator. Plant growth regulators are naturally produced by plants and are critical for regulating their own growth. Plant growth regulators act via modifying or controlling plant growth processes, such as leave and flower formation, stem elongation, as well as fruit development and ripening. In vitro: Brassinolide induced the time and concentration-dependent cytotoxicity in PC-3 cells. The mode of such cell death appeared to be apoptosis predominately, as demonstrated by fluorescence, flow-cytometric analyses and transmission electron microscopes. Moreover, Caspase-3 activity was increased after brassinolide treatment obviously. Western blot studies showed brassinolide treatment triggered a time-dependent decrease in the expression of Bcl-2 [1]. In vivo: Brassinolide had the similar function of reducing the blood glucose levels as phenformin, but without the dose-dependent manner. The blood glucose levels showed significant differences after brassinolide treatment with different doses (200, 100, and 50 mg/kg). These results indicated that brassinolide could reduce the blood glucose levels without toxicity [2]. Clinical trial: So far, no ......
[Apoptosis]

Cycloheximide,66-81-9,IC-0200336

Price : $90.00Price : ￥900.00

Cycloheximide is an antibiotic that inhibits protein synthesis at the translation level, acting exclusively on cytoplasmic (80s) ribosomes of eukaryotes. Cycloheximide affected all the energy-dependent stages in the protein-synthesizing process. However, the initiation seems the most sensitive. Cycloheximide also affects respiration, ion uptake, amino acid biosynthesis, and DNA and RNA synthesis, effects that are probably secondary to its effect on protein synthesis.[1] In vitro study indicated that Cycloheximide at 1 μM inhibited [3H]leucine incorporation into both cellular and secreted proteins by at least 86%, without having deleterious effects on membrane integrity as indicated by trypan blue uptake and lactate dehydrogenase release. Larger size class polysomes (7+) were increased by Cycloheximide treatment and remained increased during recovery. [2] In vivo analysis indicated that Cycloheximide produced initial hyperactivity. This initial hyperactivity was apparent within 3 minutes after injection of the Cycloheximide. Cycloheximide affects activity by acting on the brain, and this is unrelated to its inhibition of protein synthesis. In addition, Cycloheximide’s ef......
[Apoptosis]

A-1210477,1668553-26-1,IC-0203738

Price : $39.90Price : ￥399.00

A-1210477 is an effective and specific MCL-1 inhibitor with an EC50 value below 5 µmol/L [1]. Selectively, it binds to MCL-1 with an affinity of 0.45 nM [2]. MCL-1, an anti-apoptotic Bcl-2 family member, is an anti-apoptotic protein. It is a key regulator of cancer cell survival [3, 4]. In MCL-1-dependent SVEC cells, treatment with A-1210477 at varying doses, induced cell death in a dose-dependent manner. SYTOX Green exclusion and live-cell imaging were used to determine cell viability. In line with increased potency, cell death was more rapidly induced by A-1210477. To examine the selectivity of A-1210477 for targeting Bcl-2 family members, BcL-xL-, BcL-2-, and MCL-1-dependent SVEC cells were treated with A-1210477. A-1210477 only killed MCL-1-dependent cells. Compared with UMI-77, A-1210477 showed greater potency and specificity as an MCL-1 inhibitor, the EC50 value of UMI-77 is 10 µmol/L [1]. In living cells, A-1210477 disrupted BIM/MCL-1 complexes. In MCL-1-dependent cancer cells, A-1210477 induced the hallmarks of mitochondrial apoptosis. In various malignant cell lines, A-1210477 induced apoptosis, synergizing with navitoclax. Data also demonstrate that A-1210477 ......
[Apoptosis]

ABT-199,1257044-40-8,IC-0203927

Price : $90.00Price : ￥900.00

Venetoclax (ABT-199, GDC-0199) is a selective inhibitor of Bcl-2 with a K i of 0.01 nM in cell-free assays. Compared to Bcl-XL and Bcl-W more than 4800 times more selective, no inhibitory activity against McL-1[1]. ABT-199 cell killing was selective and mechanism dependent, BCL2high status is thus a potential predictive marker for sensitivity to ABT-199[1].BIM binding to BCL2 correlates with ABT-199 response and further showed that knockout of BIM results in decreased ABT-199 sensitivity. Eexpression of B-cell genes as enriched in ABT-199-sensitive myeloma, although no single gene consistently delineated sensitive and resistant cells[4]. In the ABT-199-resistant OCI-AML3 cell line, CXCL12 promoted an increase in the proportion of cells expressing high levels of embryonic stem cell core transcription factors abrogated by CD44 knockdown[7].The T-ALL cell line LOUCY, which shows a transcriptional program related to immature T-ALL, exhibited high in vitro and in vivo sensitivity for ABT-199 in correspondence with high levels of BCL-2. In addition, ABT-199 showed synergistic therapeutic effects with different chemotherapeutic agents[3].When performed a genome-wide CRISPR kn......
[Apoptosis]

ABT-263,923564-51-6,IC-0204116

Price : $97.50Price : ￥975.00

ABT-263 (Navitoclax) is a inhibitor of Bcl-xL, Bcl-2 and Bcl-w, with Ki ≤0.5 nM, ≤1 nM and ≤1 nM respectively[1]. ABT-263 (Navitoclax) is senolytic in some, but not all types of senescent cells: Navitoclax reduced viability of senescent human umbilical vein epithelial cells (HUVECs), IMR90 human lung fibroblasts, and murine embryonic fibroblasts (MEFs)[2]. Navitoclax (1μM ; 60 hours) accelerates apoptosis mainly by inhibiting Bcl-xL[8]. ABT-263 (Navitoclax)exhibited modest (IC50=3-8 μM) single agent potency in 8 ovarian cancer cell lines. Navitoclax(0.4μM;30h) enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells [3]. Multiple lymphoid subpopulations isolated from the thymi or BM of vavP-Bcl-2 transgenic mice were markedly more sensitive to ABT-263 (Navitoclax)[4]. ABT-263 (Navitoclax) (100 mg/kg/d;p.o;once daily for 21 days) treated a mouse model inoculated with H345 cells, and significant antitumor efficacy was observed [6]. Navitoclax with venetoclax and chemotherapy was well tolerated and had promising efficacy in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma[5]. In 44 xenograft mo......
[Apoptosis]

S63845,1799633-27-4,IC-0204305

Price : $148.50Price : ￥1485.00

S63845 is a small molecule MCL1 inhibitor with Ki < 1.2 nM [1]. Myeloid cell leukemia 1 (MCL1) is a pro-survival protein and belongs to BCL-2 family proteins. BCL-2 family proteins are key regulators of the mitochondrial apoptotic pathway. MCL1 is overexpressed in many cancers, so inhibitors targeting this protein may kills MCL1-dependent cancer cells [1]. S63845 is a highly selective and potent MCL1 inhibitor. S63845 bound human MCL1 with KD value of 0.19 nM. S63845 was approximately 1,000-fold more potent in killing MCL1-dependent H929 multiple myeloma cells than MCL1 inhibitor A-1210477. S63845 also induced caspase-dependent phosphatidyl-serine exposure, PARP cleavage and cytochrome c release from mitochondria. In HeLa cells, S63845 disrupted binding of BAK and BAX to MCL1. S63845 killed cancer cells through activation of the BAX/BAK-dependent mitochondrial apoptotic pathway by direct inhibition of MCL1 [1]. In immunocompromised mice with human multiple myeloma (H929 and AMO1) xenografts, intravenously injected (i.v.) S63845 showed dose-dependent anti-tumour activity with maximal tumour growth inhibition (TGImax) of 103% and 114% in the H929 and AMO1 model, respectiv......

< 12 3 4 5 >

InCellGene LLC.

FOLLOW US

E-mail

Password